Lyophilisation (or freeze-drying) in the pharmaceutical field has seen steady expansion combined with on-going development. Demand for lyophilisation within the pharmaceutical and biopharmaceutical sectors is expected to increase in the coming years, with a projected compound annual growth rate (CAGR) of 10.4% through to 2018 and the generation of composite revenues of US$28.7bn by this time (up from $17.6bn in 2013). This is in part fuelled by the multiple benefits that lyophilisation brings to a range of pharmaceutical products, including increased shelf life, preservation of potency and protection from degradation.
The forecast growth will mean greater need for lyophilisation equipment and capabilities, together with specialist knowledge and established experience. CDMOs must address this, in part through an extension of their current facilities or through modifications made to current equipment. Forward-looking CDMOs have responded to this demand by investing in high grade technology and facilities geared towards meeting the growth predicted for the future.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.